SAN FRANCISCO, Oct. 18, 2016 /PRNewswire/ -- Nektar
Therapeutics (Nasdaq: NKTR) ("Nektar") today announced the pricing
of its previously announced underwritten public offering of
$175.5 million in aggregate gross
proceeds, or 13,000,000 shares of its common stock at a public
offering price of $13.50 per share.
In connection with this offering, Nektar has also granted to the
underwriters a 30-day option to purchase up to an additional
1,950,000 shares of common stock at the offering price.
J.P. Morgan is acting as lead book-running manager in the
offering. Jefferies and Piper
Jaffray are acting as book-running managers. William Blair is acting as lead manager for the
offering, and Brean Capital, BTIG, Janney
Montgomery Scott, Ladenburg Thalmann and ROTH Capital
Partners are acting as co-managers for the offering.
Nektar intends to use the net proceeds from this offering for
general corporate purposes including research and development
funding and working capital.
The securities described above are being offered by Nektar
pursuant to an effective shelf registration statement, including a
prospectus supplement and accompanying prospectus, copies of which
may be obtained from the offices of J.P. Morgan Securities
LLC, attention Broadridge Financial Solutions, 1155 Long Island
Avenue, Edgewood, New York, NY
11717, or telephone: 866-803-9204.
This press release does not constitute an offer to sell, or the
solicitation of an offer to buy these securities, nor will there be
any sale of these securities in any state or other jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
Contact:
Nektar Therapeutics
Jennifer Ruddock 415-482-5585
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nektar-therapeutics-prices-public-offering-of-shares-of-common-stock-300347360.html
SOURCE Nektar Therapeutics